Top 50 Biotechnology Angel Investors in Europe (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
32 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Charlie Songhurst
Angel
|
7 | United Kingdom, United States, Germany | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $542k–$8.5M |
|
Nadav Rosenberg
Angel
|
6 | United Kingdom, France, Israel | Seed, Pre-Seed, Series A | Software, Biotechnology, Artificial Intelligence | $850k–$21M |
|
Bernard Majoie
Angel
|
5 | France, Belgium | Seed, Pre-Seed, Series A | Biotechnology, Medical, Health Care | $1.3M–$2.7M |
|
Stefano Bernardi
Angel
|
5 | Italy, United Kingdom, France | Seed, Pre-Seed | Software, Blockchain, Biotechnology | $100k–$45M |
|
Jude Gomila
Angel
|
4 | United States, United Kingdom, India | Seed, Pre-Seed, Angel | Software, Information Technology, Biotechnology | $70k–$5M |
|
Edward Lando
Angel
|
4 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, FinTech | $125k–$37M |
|
Milad Alucozai
Angel
|
4 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $110k–$60M |
|
Andrea Dusi
Angel
|
4 | Italy, United States, United Kingdom | Seed, Pre-Seed, Angel | Biotechnology, FinTech, Software | $150k–$6M |
|
Darrin Disley
Angel
|
4 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | $458k–$3.7M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
Nadav Ben-Chanoch
Angel
|
4 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Information Technology, Artificial Intelligence | $120k–$30M |
|
Peder Nielsen
Angel
|
4 | United Kingdom | Seed, Convertible Note | Biotechnology | |
|
Annie Vereecken
Angel
|
4 | Belgium | Seed, Series A | Medical, Biotechnology, Hospital | $2M–$30M |
|
Sake Bosch
Angel
|
4 | The Netherlands, France, Israel | Seed, Series A, Series B | Software, E-Commerce, Biotechnology | $1.3M–$77M |
|
Paul Wicks
Angel
|
3 | United Kingdom, United States, Japan | Seed, Pre-Seed, Series A | Software, Wellness, E-Commerce | $539k–$11M |
|
Pierre Drion
Angel
|
3 | Belgium | Series A, Series B | Biotechnology, Health Care, Life Science | $8.8M–$26M |
|
John Purdy
Angel
|
3 | Ireland | Seed, Pre-Seed, Venture - Series Unknown | SaaS, Software, Banking | $576k–$1.1M |
|
Andrew Keys
Angel
|
3 | United States, India, Norway | Seed, Pre-Seed, Series A | Software, Finance, Blockchain | $1M–$34M |
|
Inaki Berenguer
Angel
|
3 | Spain, United States, United Kingdom | Seed, Angel, Pre-Seed | FinTech, Financial Services, E-Commerce | $233k–$9M |
|
Hugh Grant
Angel
|
3 | United Kingdom | Seed, Convertible Note | Biotechnology | |
|
DrPano Kroko Churchill
Angel
|
3 | United Kingdom | Angel, Series A | Health Care, Therapeutics, Biotechnology | $150k–$458k |
|
Ludwig Cramer-Klett
Angel
|
3 | Germany | Seed, Pre-Seed | Food Processing, Biotechnology, Food and Beverage | $2M–$2.8M |
|
Ian Hogarth
Angel
|
3 | United Kingdom, United States, Germany | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $698k–$43M |
|
Jeff Dean
Angel
|
3 | United States, United Kingdom, Japan | Seed, Series A, Pre-Seed | Artificial Intelligence, Information Technology, Software | $450k–$60M |
|
David Helgason
Angel
|
3 | United States, Denmark, Finland | Seed, Series A, Pre-Seed | Software, Gaming, Artificial Intelligence | $242k–$30M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $983k–$8.1M |
|
Romain Sautrau
Angel
|
3 | France, Denmark | Series A, Seed, Pre-Seed | Biotechnology, Agriculture, AgTech | $1.1M–$12M |
|
Schnidar Harald
Angel
|
3 | Austria | Seed, Angel, Pre-Seed | mHealth, Software, Biopharma | |
|
Taavet Hinrikus
Angel
|
3 | United Kingdom, United States, Estonia | Seed, Series A, Series B | FinTech, Software, Financial Services | $1M–$50M |
|
Fabio Mondini de Focatiis
Angel
|
2 | Italy, France, United Kingdom | Seed, Pre-Seed, Equity Crowdfunding | E-Commerce, Retail, Information Technology | $329k–$2.9M |
|
Holger Hübner
Angel
|
2 | Germany | Seed, Pre-Seed | B2B, SaaS, Audio | $177k–$987k |
|
Giampaolo Cagnin
Angel
|
2 | Italy, Denmark | Seed, Pre-Seed | Biotechnology, Food and Beverage, Plant-Based Foods | $4.2M–$7.6M |
|
Sauli Törmälä
Angel
|
2 | Finland | Seed | Life Science, Biotechnology | |
|
Andrew Nutter
Angel
|
2 | France, United Kingdom, United States | Seed, Pre-Seed, Series A | Software, SaaS, FinTech | $550k–$4.9M |
|
Mark Evans
Angel
|
2 | United Kingdom, United States, The Netherlands | Series A, Seed | Retail, Fashion, Software | $1.4M–$24M |
|
Vishal Gulati
Angel
|
2 | United Kingdom, Hungary | Seed, Series A, Series B | Biotechnology, Biopharma, Life Science | $2.1M–$30M |
|
Pratima Aiyagari
Angel
|
2 | United Kingdom, France, Germany | Seed, Pre-Seed, Series A | SaaS, Software, Analytics | $982k–$12M |
|
Michael Novogratz
Angel
|
2 | United States, India, Germany | Seed, Series A, Series B | Blockchain, FinTech, Cryptocurrency | $1.1M–$150M |
|
Hampus Jakobsson
Angel
|
2 | Sweden, Denmark, United States | Seed, Angel, Series A | Health Care, Software, Artificial Intelligence | $96k–$30M |
|
Jan Hruska
Angel
|
2 | United Kingdom | Seed | Medical, Health Care, Life Science | |
|
Ed Parkinson
Angel
|
2 | United Kingdom | Seed | Health Care, Life Science, Biotechnology | $1.9M–$3M |
|
André-Jacques Auberton-Hervé
Angel
|
2 | France | Seed, Series A | Medical, Biotechnology | |
|
Luc Vauterin
Angel
|
2 | Belgium | Seed, Series A | Life Science, Data Integration, Data Visualization | |
|
Jon Oringer
Angel
|
2 | United States, France, United Kingdom | Seed, Pre-Seed, Series A | Software, Information Technology, Health Care | |
|
Juan Knuth
Angel
|
2 | Spain | Seed, Series A | Health Care, Biotechnology, Digital Media | |
|
Barbara Castellano
Angel
|
2 | Italy | Pre-Seed | Health Care, Biotechnology, Medical Device | |
|
Leena Niemistö
Angel
|
2 | Finland, United States | Seed, Pre-Seed | Health Care, Software, E-Commerce | $480k–$3.2M |
|
Nicolas Douay
Angel
|
2 | France, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Information Technology | |
|
Rolf Schromgens
Angel
|
2 | Germany, Spain, United States | Seed, Pre-Seed, Series A | Internet, Software, Information Technology | |
| Access all 50 angel investors in Europe Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 62
- Round size: Seed $537k–$25M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
- Nuclera — Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 214
- Round size: Seed $1.1M–$8.5M; Pre-Seed $542k–$5.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skrap — Skrap is an on-demand mobile marketplace for skip hire and other waste collection services.
- Uncovr — Surgical video is the biggest dark data in medicine. We turn it into operative reports, billing codes, and clinical intelligence automatically
- Structured AI — Construction AI QA/QC software that automatically reviews drawing packages and catches errors, code issues, and coordination clashes before they reach the field.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Israel
Investor stats
- Total investments: 15
- Round size: Seed $850k–$3.1M; Pre-Seed $2M–$2M; Series A $18M–$21M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Teora — Crude oil derived products have infiltrated every industry – synthetic colors, flavors, fragrances in food, dyes in textiles, fertilizers and packaging material that harm humans and the planet. TeOra’s mission is to replace synthetics with naturals that are manufactured in a sustainable and predictable manner. A microorganism is the best factory,optimized over billions of years of evolution and TeOra designs it to produce desired products. Using microfluidics and AI, TeOra offers 100 times faster and cheaper design of smart micro-organisms in weeks to months instead of years.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Lindus — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
Bernard Majoie - President @ Fournier-Majoie
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: France, Belgium
Investor stats
- Total investments: 6
- Round size: Seed $1.3M–$2.7M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- reMYND — Driving the development of disease-modifying treatments
- AgenT — AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms.
- PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Blockchain, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: Italy, United Kingdom, France
Investor stats
- Total investments: 17
- Round size: Seed $100k–$45M; Pre-Seed $874k–$2.2M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Freatic — Building the monetization layer for your alpha
- Niulinx — Niulinx specializes in providing autonomous driving technology solutions based on artificial intelligence, connectivity, and data analytics.
- Automated Architecture — A global ecosystem of automated micro-factories, to deliver sustainable, affordable and beautiful architecture to millions of people.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 64
- Round size: Seed $1.4M–$5M; Angel $70k–$1.3M; Pre-Seed $660k–$2.9M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Vaire — Conventional chips waste all their energy as heat. Vaire's groundbreaking technology will recover and recycle most of its energy, delivering low energy, high performance compute for the AI era.
- Clara — Clara is an AI-powered primary care doctor.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 478
- Round size: Seed $975k–$7M; Pre-Seed $125k–$3.4M; Series A $5.5M–$37M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Humera — Humera - AI CAPTCHA That Knows You're Human
- Allonic — Allonic is a robotics hardware company pioneering 3D Tissue Braiding, a new manufacturing platform for producing integrated, compliant, bio-inspired robotic bodies through a single, fully automated production process. By eliminating assembly-heavy designs and supply-chain complexity, Allonic enables significantly faster iteration, lower costs, andsafer, more dexterous robots to be built. Originally founded from Hungary and operating internationally with a US HQ and a growing team of 15, Allonic is building the hardware foundation for the next generation of intelligent machines.
- Heywa Labs — Heywa Labs develops Generative UX (GenUX), an AI-driven interface layer that creates dynamic, adaptive user experiences beyond static text or links. Their flagship app, Heywa, delivers visual, tappable "stories" of cards for tasks like cooking, travel, fitness, and DIY, reconfiguring in real-time based on user interactions.
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 55
- Round size: Seed $1M–$7M; Pre-Seed $110k–$5M; Series A $13M–$60M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Replit — Replit is a simple yet powerful online IDE, Editor, Compiler, Interpreter, and REPL. Code, compile, run, and host in 50+ programming languages.
- Revalia Bio — Revalia Bio develops curative drugs for chronic organ-centered disease.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Entrepreneur and investor. After working in management consulting, in 2006 he created Wish Days, known above all for the Emozione3 gift boxes. In April 2016, he sold the company to the Smartbox group with a millionaire exit. In 2017, together with Cristina Pozzi, already a partner in Wish Days he founded the no-profit organization Impactscool, withthe aim to bring education on exponential technologies to Italian students and teachers. Impactscool was sold in 2025 with an exit to an Italian bank. Now his focus is manly on studying, exploring the potential of human beings, understanding true meaning of life, enjoying the passage of time. He is advisor of dozens of technological initiatives and business angels in 150+ startups focusing on clean tech.He is the author of the book “Come far fallire una startup ed essere fellici” – How to make a startup fail and be happy, published by Bompiani, Bestseller in 2018.
Show more...Investment focus
- Industry: Biotechnology, FinTech, Software
- Stage:Seed, Pre-Seed, Angel
- Geography: Italy, United States, United Kingdom
Investor stats
- Total investments: 17
- Round size: Seed $150k–$6M; Angel $170k–$2.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- CitizenX — CitizenX is the secure and private platform that helps you diversify your passport portfolio, ensuring a safe future for you and your loved ones.
- Talyn Air — Inspired by two-stage rockets, our innovative eVTOL uses two flight vehicles to transform flight. Fixed-wing performance with VTOL capabilities.
- CaSRevolution — A novel disease-modifying approach against neurodegeneration
Darrin Disley is based out of Cambridge, Cambridgeshire, and is the Executive Chairman and Director of Cardiogeni. Darrin previously worked at Mogrify as Chief Executive Officer, Director, and Investor. Darrin Disley attended the University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 5
- Round size: Seed $458k–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- bit.bio — Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Nadav Ben-Chanoch
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 226
- Round size: Seed $500k–$6M; Pre-Seed $120k–$2.5M; Series A $4M–$30M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- micro1 — We help companies hire and manage the best software engineers easily.
- TRIVER — Triver develops online and digital tools to assist and support various financial services. It is based in London, England.
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Annie Vereecken
Show more...Investment focus
- Industry: Medical, Biotechnology, Hospital
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $2M–$6M; Series A $8.2M–$30M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- LynxCare — Continuously improving patient outcomes with previously unavailable insights. Find out more here.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Sake Bosch is a Founder and Managing Partner of Prime Ventures since 1999. Sake brings over 25 years of experience in marketing and sales and venture capital to Prime. Prior to founding Prime in 1999, Sake was a Senior Principal at Holland Venture and was responsible for managing investments in technology companies. Sake was involved in many ofthe Holland Venture technology investments including Applicare Medical Imaging (acquired by GE Medical Systems), BWise (acquired by Nasdaq), SQL Systems (acquired by Datastream) and Freecom (acquired by Mitsubishi Kagaku Media). Before joining Holland Venture in 1994, Sake worked as an Independent Corporate Finance Consultant focusing primarily on early stage companies. Prior to this position Sake was a Sales Executive at Securitas Group. Sake started his career in 1989 as a Strategic Market Analyst at VNU. Sake serves on the board of directors of Civolution, 4C, Dealerdirect, Digital Origin, Greetz, Forcare, SaaSPlaza, SlimPay and Takeaway.com. Previous investments include: 3mensio Medical Imaging (acquired by Esaoto), eBuddy (acquired by Booking.com), Global Collect (acquired by General Atlantic), MarketXS (acquired by Markit), Nedstat (acquired by comScore Inc.), Tridion (acquired by SDL) and Watermark (acquired by Qurius). Sake holds an M.Sc. degree in Business Administration as well as a B.A. degree in Management Science and Industrial Engineering.
Show more...Investment focus
- Industry: Software, E-Commerce, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: The Netherlands, France, Israel
Investor stats
- Total investments: 33
- Round size: Seed $1.3M–$7.2M; Series A $6.9M–$29M; Series B $7.1M–$77M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Alfa AI — Alfa AI is a recruitment technology company specializing in AI-driven hiring solutions.
- TerraSpark — TerraSpark Energy specializing in software solutions for renewable energy asset management. The product, TerraSpark Hub, provides comprehensive oversight of commercial and technical data for green energy assets like solar and wind projects.
- Recupere Metals — Recupere Metals focused on recycling copper scrap into high-quality electrical wires. It uses a patented mechanical process enhanced by AI to boost conductivity from impure scrap, bypassing energy-intensive smelting.
Paul Wicks, Ph.D., is a strategic advisor and independent consultant who helps digital health and life science companies turn data into evidence, evidence into influence, and influence into impact. He has supported over 40 organizations including AstraZeneca, Ada Health, Biogen, Click Therapeutics, and Woebot.Previously, Paul spent 13 years as VPof R&D at PatientsLikeMe, building one of the world’s largest patient communities and pioneering decentralized trials, digital biomarkers, and real-world evidence. He has authored over 200 peer-reviewed papers and served on editorial boards of journals including the BMJ, Digital Biomarkers, and BMC Medicine.A neuropsychologist by training, Paul completed his Ph.D. at King’s College London and a postdoc on the psychology of Parkinson’s disease. His work has been featured by BBC, CNN, and The New York Times. He was named MIT Technology Review’s “Humanitarian of the Year” in 2011 and is a TED Fellow and FLIER alumnus of the Academy of Medical Sciences. He is an honorary Professor at the University of Birmingham.
Show more...Investment focus
- Industry: Software, Wellness, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 17
- Round size: Seed $3M–$6.6M; Pre-Seed $539k–$1M; Series A $6.7M–$11M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Stelia — Stelia builds distributed AI platforms that scale globally. Research-driven intelligent systems for healthcare, education, and enterprise operations worldwide
- Epiminds — Epiminds develops multi-agent AI systems to run marketing end-to-end.
- Scooch — All-in-one subscription to eliminate hassle from your pet healthcare. From online assessment, health tracking and AI assistant to 24/7 vet support and vet-formulated treatments.
Pierre Drion - CEO @ Petercam
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 5
- Round size: Series A $8.8M–$14M; Series B $18M–$26M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — This is the homepage of the website
John Purdy
Show more...Investment focus
- Industry: SaaS, Software, Banking
- Stage:Seed, Pre-Seed, Venture - Series Unknown
- Geography: Ireland
Investor stats
- Total investments: 5
- Round size: Seed $576k–$1.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- dimply — The experience & engagement platform for financial enterprises.
- Beyondbmi — Beyondbmi is an expert led medical approach to weight loss. We provide a convenient and scientific telehealth program designed to help your reach your health goals.
- FlowForma — Unlock competitive advantage with FlowForma, the #1 no code digital process automation software & business process management tool. Get a free trial now!
Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.
Show more...Investment focus
- Industry: Software, Finance, Blockchain
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, India, Norway
Investor stats
- Total investments: 14
- Round size: Seed $1M–$34M; Pre-Seed $1.4M–$2.5M; Series A $14M–$15M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Stackr Labs — Micro-rollups to scale web3 applications
- Zivoe Finance — Join Zivoe in disrupting predatory high-interest lending.
- Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- Industry: FinTech, Financial Services, E-Commerce
- Stage:Seed, Angel, Pre-Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 27
- Round size: Seed $500k–$9M; Angel $233k–$1M; Pre-Seed $1.2M–$2M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Goin — Goin is a Barcelona-based fintech platform founded in 2017 that provides a unified money optimization ecosystem combining automated savings, investments, digital assets, and rewards. The app enables users to aggregate multiple bank accounts via PSD2, centralizing financial data and automating decisions through its AI engine, gaIA. Goin integratesfinancial automation, portfolio tools, and cash-back incentives in a single interface used primarily by young European consumers. The company operates in a regulated environment, is registered with the Bank of Spain as a crypto service provider, and has expanded across Southern Europe. In 2025, Goin launched KernelPay, its B2B Banking-as-a-Service (BaaS) infrastructure for payments, accounts, and wallet management.
- Permisso — Bankflip is a mobile application that collects and processes income, tax, employment, and relevant data in real-time.
- Momento — Momento is an insurtech company with the objective of revolutionizing the insurance industry in Latin America, starting with car insurance. We want to make insurance easy and accessible for the underserved population in LATAM.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Hugh Grant is the Chief Executive Officer at H.B.Grant and Associates.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Industry: Health Care, Therapeutics, Biotechnology
- Stage:Angel, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Round size: Angel $150k–$458k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Ludwig Cramer-Klett is an Entrepreneur and Investor.
Show more...Investment focus
- Industry: Food Processing, Biotechnology, Food and Beverage
- Stage:Seed, Pre-Seed
- Geography: Germany
Investor stats
- Total investments: 4
- Round size: Seed $2M–$2.7M; Pre-Seed $2M–$2.8M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
- Kynda — Kynda produces vegan foods and mycelium using accessible biotechnology for meat alternatives. They provide services for agri food companies, consumer packaged goods manufacturers, and biotech companies.
- Kynda — Keen 4 Greens offers a wide range of vegan products. Founded in 2019, Keen 4 Greens is based in Hamburg, Germany.
Ian Hogarth is based out of London, England, and is the Chairman of Phasecraft. Ian previously worked at Songkick as a Chairman. Ian Hogarth attended the University of Cambridge.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 60
- Round size: Seed $1.5M–$7.9M; Pre-Seed $698k–$7.5M; Series A $11M–$43M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
- Cordless — Bridging the gap between voice and text
- Fabric — Fabric is an AI-powered workspace and file manager for people and groups.Fabric is a self-organizing multiplayer workspace.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Japan
Investor stats
- Total investments: 104
- Round size: Seed $2.5M–$35M; Pre-Seed $450k–$2.3M; Series A $10M–$60M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Moonlake AI — Vibe code games and worlds into existence.
- Belfort — Enabling Fully Homomorphic Encryption through Hardware Acceleration
- Periodic Labs — From bits to atoms.
David is a technologist, the founder of Unity Technologies, non-exec director to others, and a restless entrepreneur with a passion for creating feedback loops between innovation and teams and products, applying new and old business models to changing industries, and pushing people to do the very best they can do.David's background is inprogramming, an assortment of university dabbling, creating companies, and helping entrepreneurs. He served as CEO of Unity Technologies since co-founding it in 2003 and until October 2014, with an unflinching vision to democratize game development, and to develop technology and business models for the next phase of the games industry. David Helgason attended the University of Copenhagen.
Show more...Investment focus
- Industry: Software, Gaming, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Denmark, Finland
Investor stats
- Total investments: 79
- Round size: Seed $1.1M–$8M; Pre-Seed $242k–$2.4M; Series A $4.3M–$30M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- ScyAI — Risk intelligence that thinks with you.
- Noah — API-first stablecoin payments, enterprise-grade compliance and real-time settlements, powered by stablecoin technology.
- Flow Engineering — Requirements management, made collaborative
Nicholas Francis is based out of Copenhagen, Hovedstaden, and is the Founder of Francis Family Funds. Nicholas previously worked at framebunker as a Co-Founder.
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $983k–$8.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan creates a water resilience planning platform for managing water availability in facilities. The company employs artificial intelligence to automatically collect operational data from businesses and combine it with local water satellite imagery to provide a real-time financial assessment of water risk and to offer modified mitigation andadaptation options.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Romain Sautrau is a Investment Director at Supernova Invest. Romain attended INSEAD.
Show more...Investment focus
- Industry: Biotechnology, Agriculture, AgTech
- Stage:Series A, Seed, Pre-Seed
- Geography: France, Denmark
Investor stats
- Total investments: 13
- Round size: Seed $1.4M–$2.4M; Series A $1.1M–$12M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Novolyze — Novolyze is a Food Safety company. They offer solutions to help the food industry manufacture safer food, while ensuring strong compliance with international Food Safety & Quality standards. Their research work mainly focuses on evaluating the inactivation of foodborne pathogens under different kinds of stress (heat, etc.). Based on thisexpertise, they have developed the first range of dried, ready-to-use surrogate bacteria, an innovation that allows the food industry to test the efficacy of microbial kill steps / intervention steps in real-life conditions. At Novolyze, they are at the forefront of Food Safety. Their cross-functional team of experts, mainly composed of food microbiologists and process engineers, is able to assist at multiple stages of a project. Novolyze relies on state-of-the-art infrastructures, installed in a pharmaceutical-grade environment at their R&D Center in Dijon, France.
- Antofenol — Antofénol is a post-harvest biocontrol company that directs and develops its work on the valorization of viticultural waste. Antofénol is an innovative biotechnology start-up providing ecological eco-extraction of plant matter.
- nextProtein — nextProtein is developing a large scale and sustainable insect based source of protein. The bioconversion of fly larvae fed with organic waste generates valuable feed components for fish, livestock and pets.
Entrepreneur, Angel Investor, Scientist and Inventor
Show more...Investment focus
- Industry: mHealth, Software, Biopharma
- Stage:Seed, Angel, Pre-Seed
- Geography: Austria
Investor stats
- Total investments: 7
- Lead/follow: 86% lead, 14% follow
Portfolio highlights
- SCARLETRED — SCARLETRED is an international Digital Health Scaleup revolutionising the global skin care market by the AI powered SCARLETRED®VISION platform system. The problem we solved is subjective skin assessment and lacking standardization in Dermatology. Our medical device certified platform is fully mobile, runs via mobile App on smartphones and connectsto our web platform, which enables to generate smart imaging data and novel AI decision support applications in Dermatology and Telemedicine. The multi award winning technology is supplied international via SaaS to Biopharma and Cosmetics Industry, Hospitals and Medical Experts. Protected via worldwide patents it facilitates standardized skin documentation and remote tracking of skin changes and therapeutic effects via mobile App. Images can be uploaded in a cloud based platform and objectively analysed for visual skin changes over time, such as for allergic reactions, pigmentation changes, acne, psoriasis, disease or wound healing. SCARLETRED provides services on a broad range of dermatologic conditions ranging from B2B to B2B2C applications.
Taavet Hinrikus is based out of London, England and is the Partner of Plural Platform and Board Member of CoMind. Taavet previously worked at Wise as a Chairman and Co-founder. Taavet Hinrikus attended INSEAD.
Show more...Investment focus
- Industry: FinTech, Software, Financial Services
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Estonia
Investor stats
- Total investments: 127
- Round size: Seed $1M–$7.9M; Series A $7M–$47M; Series B $23M–$50M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Feather — Feather gives you insurance advice for expats in Germany. Our digital insurance agent will help you get the right insurance policies for your need.
- Habito — We're the Treating Customers Fairly Champion of 2023 as voted for in the British Bank Awards. We're here to make mortgages easier - no paperwork, no stress and no fees.
- Entrepreneurs First — We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Venture Partner, Eurazeo InvestmentInternational Venture Capitalist, Business Angel and SVP with >20 years experience in >20 countries, with a successful track as VC, BA and Entrepreneur in a truly global environment. Fabio is a Venture Partner in Eurazeo Investment, following their acquisition of IDINVEST Partners, a leading Europeanprivate equity firm with >9B€ AUM, focusing on Venture Capital investments in Italy across sectors and in the Smart City sector (Energy, Cleantech, Eco-mobility) worldwide. Fabio is the Founder and CEO of growth Capital, the leading Italian investment banking focusing on advising innovative, fast-growing companies on fund raising and M&A. Fabio is also an active Business Angel, with a personal portfolio of more than 30 startups. a Member of the Investment Committee of Lazio Innova. Previously Fabio has been a Senior Advisor in the European Investment Fund (EIF), leading the joint efforts of EIF and Cassa Depositi e Prestiti (CDP) to establish TT Investment Funds in Italy to develop its ecosystem for Innovation. Before entering the Private Equity sector, Fabio has lead Soitec Solar Division sale after it has increased its revenues from ~2M€ to >40M€ and achieved the world record of PV Module Efficiency and Solar Cell Efficiency. He had earlier founded and lead RenEn Renewable Energy to a leading renewable energy consulting firm. Earlier Fabio has been in McKinsey, ENEL and Russell Reynolds. In ENEL, Fabio has been Head of Integration, Head of International Management, Head of HR and Organisation and member of the Board of various international companies. Fabio received his M.S. degree in Civil and Environmental Engineering from M.I.T. and his M.B.A. from INSEAD. He is fluent in English, Italian, French and Spanish.
Show more...Investment focus
- Industry: E-Commerce, Retail, Information Technology
- Stage:Seed, Pre-Seed, Equity Crowdfunding
- Geography: Italy, France, United Kingdom
Investor stats
- Total investments: 21
- Round size: Seed $329k–$2.2M; Equity Crowdfunding $1.4M–$2.9M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Icohup — The aim of Icohup is the development of pollution sensors with high performance yet low costs.
- Yobs — Record your interviews, accelerate candidate review, coach recruiters and build a fair and rigorous hiring process.
- Keyless — Reverify and authenticate your users in a glance, without storing biometric data. PingOne Recognize delivers private, fraud-resistant biometric authentication.
Holger Hübner
Show more...Investment focus
- Industry: B2B, SaaS, Audio
- Stage:Seed, Pre-Seed
- Geography: Germany
Investor stats
- Total investments: 5
- Round size: Seed $560k–$987k; Pre-Seed $177k–$329k
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- musicube — MassiveMusic is a global music and sound partner specializing in sonic branding, sound strategy, music innovation & licensing.
- RetroBrain R&D GmbH — Memore gamifies proven dementia therapies into a gesture controlled medical video game. It incorporates and gamifies proven therapies, delaying the effects of dementia and mild cognitive impairment, enabling elderly people without prior gaming experience to utilize the gaming suite easily.Memore works both therapeutically and preventatively withnursing rehabilitation. It was founded in 2014 and is based in Hamburg, Germany.
- HorseAnalytics — HorseAnalytics empowers horse enthusiasts to monitor and improve health and training of horses by applying reliable technologies from health and sports supervision and combining constant and real-time scientific analytics.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Plant-Based Foods
- Stage:Seed, Pre-Seed
- Geography: Italy, Denmark
Investor stats
- Total investments: 3
- Round size: Seed $4.2M–$7.6M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Sauli Törmälä is the Board Member, CFO at Promilless Oy. He attended University of Oulu.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Seed
- Geography: Finland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Finnadvance — Finnadvance is an Organ-On-Chip company developing high throughput biological barriers on chips to mimic human biology such as vascular, lung and the Blood-Brain-Barriers for small molecule, micro-nano-formulation permeability and toxicity testing with in-vivo like dynamic cell cultures.
Andrew Nutter is a Co-Founder at Gama. He attended Stanford University.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: France, United Kingdom, United States
Investor stats
- Total investments: 25
- Round size: Seed $550k–$4.9M; Pre-Seed $809k–$3.4M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Yavin — Yavin provides modern point-of-sale solutions for European merchants. Yavin is a tool to receive payments, sell smarter, and grow the business.
- Gama — Thanks to cheap, reliable and scalable solar sails, we are redefining deep space access.
- EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more...Investment focus
- Industry: Retail, Fashion, Software
- Stage:Series A, Seed
- Geography: United Kingdom, United States, The Netherlands
Investor stats
- Total investments: 36
- Round size: Seed $1.4M–$8M; Series A $3.2M–$24M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- ONI — Where are you in your super-resolution journey? ONI is here to support you along your super-resolution journey Answer a few simple questions to discover key resources that can help you make the most of single-molecule imaging technology across a wide range of applications Products Gallery FAQs Subscribe to our mailing list
- Ufonia — Dora is a clinical AI agent that calls and supports your cataract patients, empowering your ophthalmology practice to scale without compromise on care.
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Vishal Gulati: Vishal serves as a venture partner specialising in digital health at DFJ Esprit, Europe's leading Silicon Valley style venture capital firm with over $1b under management. Since 2012, Vishal has been Europe’s leading promoter of investment into the emerging digital health sector and chairman of Digital Health Forum, whichsupports the best in class digital health companies to grow into global enterprises. Vishal serves on several boards including Horizon Discovery Group PLC (Cambridge, UK), a gene editing company; Fluidics Analytics (Cambridge, UK), a next gen protein discovery engine, Frameshift a healthcare information flow platform (London, UK) and EcoEos (San Francisco, USA), a consumer genomics business. His previous investments include Napo Pharmaceuticals, Glenmark, Renovo and Phagenesis.
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Life Science
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 8
- Round size: Seed $3.2M–$8M; Series A $2.1M–$12M; Series B $6.8M–$30M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
- Verisian — Verisian accelerates drug time to market with the industry's first platform offering real study traceability (CDISC, SDTM, ADaM, TFLs)
- Turbine — Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Industry: SaaS, Software, Analytics
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Germany
Investor stats
- Total investments: 11
- Round size: Seed $1.2M–$8.3M; Pre-Seed $982k–$1.2M; Series A $7M–$12M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Treblle — Treblle is a lightweight SDK that helps Engineering and DevOps teams build, ship & maintain REST based APIs faster
- Mindflow — Mindflow is a No-Code & Agentic Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks and to deploy AI Agents at scale.
Michael E. Novogratz is based out of New York, New York, and is the Founder and CEO of Galaxy Digital. Michael previously served at Partner and President of Fortress Investment Group. Michael E. Novogratz attended Princeton University.
Show more...Investment focus
- Industry: Blockchain, FinTech, Cryptocurrency
- Stage:Seed, Series A, Series B
- Geography: United States, India, Germany
Investor stats
- Total investments: 32
- Round size: Seed $1.1M–$8.5M; Series A $11M–$38M; Series B $15M–$150M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Curative — Get on-the-go COVID-19 testing and other essential health services, wherever you are.
- Mansa — Built by Black creators with a passion for making culture-positive content, Mansa is the only place to stream the best in Global Black stories
- Galaxy Digital — Galaxy is a digital asset and blockchain leader helping institutions, startups, and individuals shape a changing economy.
Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Seed, Angel, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 43
- Round size: Seed $310k–$5.3M; Angel $96k–$1.2M; Series A $2.3M–$30M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- ClimateView — ClimateView is a Swedish climate action technology company that helps cities transform climate planning into progress. We combine data, agent-based modelling and interface design to help cities successfully manage the transition to zero carbon economies.
- Mojo — Clinical-grade, AI-powered sperm analysis from the comfort of home. Test your sperm count, motility, morphology and much more with the Mojo kit. Check your fertility from home at low cost - without the need for clinic visits and awkward waiting rooms.
- Volta Greentech — Discover innovative solutions to reduce agricultural emissions with Volta Greentech's science-driven feed additives, promoting sustainable farming and planetary health.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Jan Hruska
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Ed Parkinson
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $1.9M–$3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
Dr. André-Jacques Auberton-Hervé co-founded Soitec with Jean-Michel Lamure in 1992. As President, CEO and Chairman of the Board, Auberton-Hervé is responsible for overseeing the strategic, operational and financial activities of the company.Prior to founding Soitec, Auberton-Hervé managed several joint development programs between Leti andThomson-CSF, which focused on the technological transfer from R&D to production applications. These programs included the transfer of 1.2 µm and 0.8 µm SOI CMOS for space applications. He was also in charge of several projects, which applied SOI to 3D integration, VLSI and ULSI.In July of 2005, Auberton-Hervé was elected to serve as the European representative to SEMI’s International Board of Directors. His demonstrated vision, experience and leadership capabilities within the industry contributed to his appointment to the board. Auberton-Hervé is also the recipient of the 1999 European SEMI Award in recognition of his work on Smart Cut™ technology and his overall contributions to the semiconductor industry as a whole. Auberton-Hervé is a member of the Electrochemical Society and the IEEE.
Show more...Investment focus
- Industry: Medical, Biotechnology
- Stage:Seed, Series A
- Geography: France
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- LinKinVax — As part of our strategic evolution, EnnoDC has become the new trading name of LinKinVax. We're expanding our dendritic cell targeting technology and
Luc Vauterin - Board Member @ ONTOFORCE
Show more...Investment focus
- Industry: Life Science, Data Integration, Data Visualization
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 119
- Lead/follow: no public data
Portfolio highlights
- SLUSHY — SLUSHY is a secure mobile web based platform for content creators to find, grow, & monetize their audiences. A creator first, tech-driven tool, designed with key discoverability features and audience insights. In a market where existing solutions (OnlyFans, Patreon) fall short of their creators' demands, SLUSHY provides an alternativesolution for professional content creators that prioritizes their monetization, support and management needs. SLUSHY incorporates a powerful legal framework, with robust compliance tools including simplified consent, ID verification, and content moderation. The new home of unrestricted content, SLUSHY is here.
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
- Unsloth AI — Open source fine-tuning & reinforcment learning (RL) for gpt-oss, Llama 4, DeepSeek-R1, Gemma, and Qwen3 LLMs! Beginner friendly.
Juan Knuth
Show more...Investment focus
- Industry: Health Care, Biotechnology, Digital Media
- Stage:Seed, Series A
- Geography: Spain
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Devicare — Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The company's medical devices are useful in measuring the level of biomarkers in body fluids such as saliva, tears, sweat, sputum, feces, urine or blood, enabling medical professionals to detect and treat various infectious diseases.
Laura Iris Ferro
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Pre-Seed
- Geography: Italy
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Newronika — Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.
- Bio4Dreams — Il primo incubatore italiano certificato di startup innovative in fase very early stage, a capitale totalmente privato, dedicato alle Scienze della Vita.
- CorFlow Therapeutics AG — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Leena Niemistö
Show more...Investment focus
- Industry: Health Care, Software, E-Commerce
- Stage:Seed, Pre-Seed
- Geography: Finland, United States
Investor stats
- Total investments: 19
- Round size: Seed $480k–$3.2M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Vapaus — A circular economy startup Vapaus provides sustainable mobility solutions – Employee benefit bicycles and shared electric vehicles as a ready-to-use serviceWith its services, Vapaus supports customers’ to create and strengthen a better experience of the work community, to save on the costs of commuting and business travels, and to move towardssmarter and more environmentally friendly modes of transport, both at work and in employees’ leisure time.Every kilometer traveled by the Vapaus mobility solution removes carbon dioxide from the air, helping not only the environment but also customers on their way to carbon neutrality. The mission of Vapaus is to be a global leader when it comes to sustainable Corporate Mobility.
- ADESANTE — SurgeryVision is a Virtual Reality solution for Surgeons. Product is intended to be used for planning surgical procedures.
- Maire — Maire - AI co-pilot for industry leading B2C E-commerce brands. From Industry Trends to Market Research and Search Intent Analysis
Previously cofounder @ Keldoc - currently early stage investor @ Better Angle
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 57
- Lead/follow: no public data
Portfolio highlights
- Samp — Whatever the scale, age, or number of facilities, Shared Reality helps industrial operators accelerate their digital twin programs in an affordable and accessible way.
- Ambler — Ambler is a startup founded in 2018 by experts in digital and so-called "marketplace" models 100% French, the company enjoys the support of public authorities (Wilco-ex Scientipôle) and the support of prestigious private investors , including Partech, Idinvest Partners, Kima Ventures.The startup is developing technologies to help matchthe supply and demand of medical transports. It aggregates, thanks to win-win partnerships, a considerable fleet of vehicles and offers unparalleled deliverability for contractors. Ambler is the only solution capable, nationwide, of absorbing the constant growth of health transport flows induced by demographic and regulatory factors (reform of regional hospital groups).
- Lalilo — Sign up and invite parents remotely for home access to phonics and reading lessons.
Rolf Schromgens - Co-Founder @ leadership.sprouts
Show more...Investment focus
- Industry: Internet, Software, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Spain, United States
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Langdock — Meet Langdock. Start with a GDPR-compliant daily chat companion for your employees. Then deploy more advanced AI use cases like Assistants and Workflows. All in one easily extendable platform.
- socialbnb — Explore sustainable travel with socialbnb. Book sustainable accommodations, hotels, b&bs, experiences and trips that support local communities. Travel with social impact. Discover now!
- Teech Education — Teech Education is a platform for schools to enable digital teaching.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Angel Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 angel investors investing in Europe Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!